Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application
Clinical Lymphoma Myeloma and Leukemia · 2026
DOI: 10.1016/j.clml.2025.12.016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Roberto Mina und 14 weiteren Autor:innen. Beteiligte Einrichtung: Winship Cancer Institute of Emory University, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasm, Residual. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 115 Literaturangaben. Gefördert von: Sanofi.
Abstract (Originalsprache)
Much evidence supports the assessment of minimal residual disease (MRD) status in the clinical management of multiple myeloma (MM). Using highly sensitive next-generation flow cytometry and next-generation sequencing tests to detect MRD enables clinicians to evaluate the depth of response and therefore the prognosis of patients with MM as achieving deep and sustained (≥ 12 months) undetectable MRD correlates with prolonged survival in patients with MM. Because of this, undetectable MRD (also referred to as MRD-negativity) has been recognized and approved by the FDA as an early endpoint in clinical trials to accelerate regulatory approval of new treatments for MM. However, many questions remain around how (methods, sensitivity levels), who (all patients vs. those achieving complete/partial response), and when to test in relation to treatment phases, defining the optimal duration for sustained undetectable MRD, and how MRD can be used to guide treatment strategies in clinical practice. This narrative review has examined data from key clinical trials in MM to analyze the implementation of MRD testing in the newly-diagnosed and relapsed/refractory MM settings. We have also summarized trials that test MRD-driven approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Winship Cancer Institute of Emory University, Atlanta, GA, USA.
- Haematology Unit, Careggi University Hospital, Florence, Italy.
- Hematology Unit, San Bortolo Hospital, Vicenza, Italy.
- Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, Italy.
- Hematology Unit, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.
Förderung
- Sanofi
Zitieren
APA
Mina, R., Antonioli, E., Barilà, G., Bolli, N., Botta, C., Furlan, A., Liberatore, C., Martello, M., Moré, S., Oliva, S., Rossini, B., Saraci, E., Solimando, A. G., Storti, P., & Zamagni, E. (2026). Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.12.016
Vancouver
Mina R, Antonioli E, Barilà G, Bolli N, Botta C, Furlan A, et al. Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2025.12.016
BibTeX
@article{Mina2026,
author = {Mina, Roberto and Antonioli, Elisabetta and Barilà, Gregorio and Bolli, Niccolò and Botta, Cirino and Furlan, Anna and Liberatore, Carmine and Martello, Marina and Moré, Sonia and Oliva, Stefania and Rossini, Bernardo and Saraci, Elona and Solimando, Antonio Giovanni and Storti, Paola and Zamagni, Elena},
title = {Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2025.12.016}
}
EUVIMED